Lanthio Pharma is a Dutch biopharmaceutical company committed to developing and commercializing therapeutic peptides against difficult to target receptors (e.g. GPCRs). With its proprietary LanthioPep technology, the company is generating peptide drugs that are markedly enhanced for stability and selectivity.
Utilizing our technology we are building a growing pipeline of stabilized, receptor-specific lanthipeptides with the potential for treatment of fibrosis, heart failure and multiple sclerosis.
Lanthio’s lead product, MOR107 (formerly LP2), is a selective AT2 receptor agonist, in development for Diabetic Nephropathy, with possible further applications in IPF and other fibrotic diseases.
MOR107 is currently in preclinical development.
On May 7th, 2015 MorphoSys AG announced that it has acquired all outstanding shares of Lanthio Pharma BV